Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CASI NASDAQ:ITRM NASDAQ:KZR NASDAQ:PRTG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCASICASI Pharmaceuticals$2.34+2.6%$1.74$1.09▼$7.67$28.04M0.77420,334 shs26,251 shsITRMIterum Therapeutics$0.68+7.3%$0.82$0.61▼$3.02$29.81M3.04800,763 shs492,920 shsKZRKezar Life Sciences$4.07+6.5%$4.20$3.62▼$9.18$27.97M0.6132,599 shs57,149 shsPRTGPortage Biotech$7.63+9.6%$6.97$2.81▼$23.01$8.01M0.2556,380 shs377,941 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCASICASI Pharmaceuticals+2.63%+1.30%+39.29%+25.68%-65.02%ITRMIterum Therapeutics+7.31%+0.21%-3.11%-30.08%-36.02%KZRKezar Life Sciences+6.54%+3.04%-0.73%-7.50%-28.03%PRTGPortage Biotech0.00%+5.97%-11.79%-9.27%+100.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCASICASI Pharmaceuticals$2.34+2.6%$1.74$1.09▼$7.67$28.04M0.77420,334 shs26,251 shsITRMIterum Therapeutics$0.68+7.3%$0.82$0.61▼$3.02$29.81M3.04800,763 shs492,920 shsKZRKezar Life Sciences$4.07+6.5%$4.20$3.62▼$9.18$27.97M0.6132,599 shs57,149 shsPRTGPortage Biotech$7.63+9.6%$6.97$2.81▼$23.01$8.01M0.2556,380 shs377,941 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCASICASI Pharmaceuticals+2.63%+1.30%+39.29%+25.68%-65.02%ITRMIterum Therapeutics+7.31%+0.21%-3.11%-30.08%-36.02%KZRKezar Life Sciences+6.54%+3.04%-0.73%-7.50%-28.03%PRTGPortage Biotech0.00%+5.97%-11.79%-9.27%+100.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCASICASI Pharmaceuticals 3.00Buy$4.0070.94% UpsideITRMIterum Therapeutics 3.00Buy$9.001,227.04% UpsideKZRKezar Life Sciences 2.33Hold$9.00121.13% UpsidePRTGPortage Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRTG, ITRM, CASI, and KZR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025CASICASI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.007/16/2025KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCASICASI Pharmaceuticals$28.54M1.01N/AN/A$0.12 per share19.50ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AKZRKezar Life Sciences$7M4.26N/AN/A$16.02 per share0.25PRTGPortage BiotechN/AN/AN/AN/A($0.79) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCASICASI Pharmaceuticals-$39.26M-$2.89N/A∞N/A-148.55%-1,844.13%-99.07%11/12/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%11/11/2025 (Estimated)PRTGPortage Biotech-$6.77M-$41.65N/A∞N/AN/AN/AN/A9/10/2025 (Estimated)Latest PRTG, ITRM, CASI, and KZR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q2 2025CASICASI Pharmaceuticals-$0.47-$0.86-$0.39-$0.86$6.28 million$4.18 million8/13/2025Q2 2025KZRKezar Life Sciences-$2.15-$1.87+$0.28-$1.87N/AN/A8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCASICASI PharmaceuticalsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCASICASI PharmaceuticalsN/A0.480.68ITRMIterum TherapeuticsN/A2.692.52KZRKezar Life Sciences0.037.297.29PRTGPortage BiotechN/A2.022.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCASICASI Pharmaceuticals22.23%ITRMIterum Therapeutics9.21%KZRKezar Life Sciences67.90%PRTGPortage Biotech13.36%Insider OwnershipCompanyInsider OwnershipCASICASI Pharmaceuticals21.24%ITRMIterum Therapeutics2.40%KZRKezar Life Sciences10.40%PRTGPortage Biotech42.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCASICASI Pharmaceuticals18012.30 million9.69 millionOptionableITRMIterum Therapeutics1047.17 million46.04 millionNot OptionableKZRKezar Life Sciences607.32 million6.56 millionNot OptionablePRTGPortage Biotech61.05 million608,000OptionablePRTG, ITRM, CASI, and KZR HeadlinesRecent News About These CompaniesTON Treasury Bet: AlphaTON Capital Secures $100M in Telegram-Linked CoinSeptember 5 at 7:25 PM | thecurrencyanalytics.comTTON holds steady as AlphaTON Capital unveils $100 million Toncoin treasury planSeptember 5 at 3:52 AM | fxstreet.comAlphaTON Capital Bets Big on TON With $100M Token Treasury PlanSeptember 3 at 5:21 PM | coinlaw.ioCAlphaTON Capital Launches $100M TON Treasury Strategy, Rebrands as ATON on NasdaqSeptember 3 at 5:21 PM | coingape.comCPortage Biotech, renamed AlphaTON Capital, launches TON digital asset treasurySeptember 3 at 5:21 PM | msn.comAlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram EcosystemSeptember 3 at 12:37 PM | globenewswire.comAlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram EcosystemSeptember 3 at 9:00 AM | globenewswire.comPortage Biotech Reports Results for Fiscal Year Ended March 31, 2025July 25, 2025 | globenewswire.comPortage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | NasdaqJune 27, 2025 | nasdaq.comPRTG Portage Biotech Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comPortage Biotech Inc. (PRTG) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPortage Biotech Regains Nasdaq ComplianceJune 25, 2025 | tipranks.comPortage Biotech Regains Full Compliance with Nasdaq Continued Listing RequirementsJune 25, 2025 | globenewswire.comPortage Biotech Inc. (PRTG) Cash Flow - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPortage Biotech acquires stake in Compedica for $5 millionJune 10, 2025 | investing.comPortage Biotech and Compedica Forge Strategic Alliance with Stock ExchangeJune 9, 2025 | tipranks.comPortage Biotech Inc. Enters Subscription Agreement with Compedica Holdings Limited for Strategic Equity InvestmentJune 9, 2025 | quiverquant.comQPortage Biotech and Compedica Stock-for-Stock ExchangeJune 9, 2025 | globenewswire.comPortage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human TrialApril 28, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical resultsApril 28, 2025 | za.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTG, ITRM, CASI, and KZR Company DescriptionsCASI Pharmaceuticals NASDAQ:CASI$2.34 +0.06 (+2.63%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.31 -0.03 (-1.45%) As of 09/5/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Iterum Therapeutics NASDAQ:ITRM$0.68 +0.05 (+7.31%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.70 +0.02 (+3.66%) As of 09/5/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Kezar Life Sciences NASDAQ:KZR$4.07 +0.25 (+6.54%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.90 -0.17 (-4.05%) As of 09/5/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Portage Biotech NASDAQ:PRTG$7.63 +0.67 (+9.63%) Closing price 09/3/2025 07:59 PM EasternExtended Trading$7.63 0.00 (0.00%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
